Most Recent

image: Pet Meds Adapted from Human Therapies

Pet Meds Adapted from Human Therapies

By | October 1, 2016

Companies focused on developing treatments for dogs, cats, and horses are bringing a diverse array of products to the pet medicine market.

0 Comments

image: The Narcissistic Scientist

The Narcissistic Scientist

By | October 1, 2016

Are leading researchers driven more by the quest for knowledge or the pursuit of fame?

1 Comment

image: Thirty Years of Lab Safety

Thirty Years of Lab Safety

By | October 1, 2016

From mouth pipetting to automated liquid handling, life-science labs have gotten much safer over the past three decades.

1 Comment

image: Does Productivity Diminish Research Quality?

Does Productivity Diminish Research Quality?

By | September 28, 2016

More papers correlate with top-cited research for more-established academics, but not newly minted professors, according to a study.  

3 Comments

image: Q&A: From FDA to Industry

Q&A: From FDA to Industry

By | September 27, 2016

Among a subset of US Food and Drug Administration regulators who leave the agency, more than half go to work for pharmaceutical companies, researchers report.

1 Comment

image: Allergan’s Buying Spree Rolls On

Allergan’s Buying Spree Rolls On

By | September 21, 2016

The Ireland-based pharma company makes a $1.7 billion offer to acquire Tobira Therapeutics, a US firm developing liver disease drugs.

0 Comments

image: Further Support for Early-Life Allergen Exposure

Further Support for Early-Life Allergen Exposure

By | September 20, 2016

Egg and peanut consumption during infancy is linked to lower risk of allergy to those foods later in life, according to a meta-analysis.

0 Comments

image: Feds Demand More Clinical Trial Reporting

Feds Demand More Clinical Trial Reporting

By | September 19, 2016

Expanded US Health and Human Services rules will require the results of more human studies to be made public.

1 Comment

Scientists estimate the risk to fetuses exposed to the virus in utero.

0 Comments

image: Allergan Set to Buy Vitae

Allergan Set to Buy Vitae

By | September 16, 2016

The Irish drugmaker has made a $639 million dollar offer to buy the US-based biopharma.

0 Comments

Popular Now

  1. Consilience, Episode 3: Cancer, Obscured
  2. RNAi’s Future in Drug-Target Screening
    News Analysis RNAi’s Future in Drug-Target Screening

    A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? 

  3. A History of Screening for Natural Products to Fight Cancer
  4. Streakers, Poopers, and Performers: The Wilder Side of Wildlife Cameras
AAAS